0.1409  -0.027 (-16.23%)		10-03 12:29
Open: 0.14 High: 0.1409 Volume: 6,182		Pre. Close: 0.1682 Low: 0.13 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.18	1-year :	0.21
Resists	First :	0.15	Second :	0.18
Pivot price	0.15
Supports	First :	0.11	Second :	0.09
MAs	MA(5) :	0.14	MA(20) :	0.15
	MA(100) :	0.36	MA(250) :	0.87
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	35.9	D(3) :	35.3
RSI	RSI(14): 42.8
52-week	High :	3.36	Low :	0.1

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ZVSA ] has closed above bottom band by 13.9%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.14 - 0.14	0.14 - 0.14
Low:	0.13 - 0.13	0.13 - 0.13
Close:	0.14 - 0.14	0.14 - 0.14

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Wed, 13 Aug 2025
ZyVersa Therapeutics Reports Second Quarter 2025 Financial - GlobeNewswire

Mon, 21 Jul 2025
ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Quiver Quantitative

Wed, 16 Jul 2025
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move - TipRanks

Wed, 16 Jul 2025
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com

Tue, 08 Jul 2025
FDA Grants Emergency Access to ZyVersa's VAR 200 Drug for Ultra-Rare Kidney Disease Treatment - Stock Titan

Tue, 08 Jul 2025
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	8 (M)
Shares Float	8 (M)
Held by Insiders	0 (%)
Held by Institutions	5.9 (%)
Shares Short	359 (K)
Shares Short P.Month	301 (K)

EPS	-1.95
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-24.8 %
Return on Equity (ttm)	-112.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.96
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-0.08
PEG Ratio	0
Price to Book value	0.11
Price to Sales	0
Price to Cash Flow	-0.23

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.